Hester Biosciences Ltd
₹2196.40
+38.70 (1.79%)
Fri, 23 Oct 2026, 11:59 pm
Health Technology
Pharmaceuticals: Major
24.5KHester Biosciences Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 8.13 | 6.69 | 8.74 | 7.95 | 11.32 | 7.99 | 9.49 | 9.65 | 7.99 | 31.96 | 22.13 | 27.57 | 53.25 | 31.62 | 26.98 | 47.36 | 58.75 | 48.58 | 62.57 | 38.81 |
| Price to book ratio | 2.75 | 1.38 | 1.84 | 1.03 | 1.67 | 1.26 | 1.21 | 1.57 | 1.01 | 4.83 | 4.18 | 5.32 | 9.70 | 7.41 | 3.91 | 7.14 | 8.88 | 4.62 | 4.05 | 3.39 |
| Price to sales ratio | 1.80 | 1.65 | 1.96 | 1.29 | 1.82 | 1.44 | 1.50 | 1.38 | 1.10 | 4.41 | 4.23 | 5.29 | 10.06 | 7.38 | 4.29 | 7.61 | 9.83 | 4.86 | 3.90 | 3.43 |
| Price to cash flow ratio | 20.50 | 2.86 | 6.15 | 4.79 | 4.98 | 7.43 | 6.30 | 10.60 | 23.61 | 20.85 | 27.87 | 20.69 | 40.05 | 31.50 | 26.69 | 29.49 | 353.52 | 112.34 | 33.64 | 20.43 |
| Enterprise value | 37.63Cr | 49.91Cr | 81Cr | 55.75Cr | 87.46Cr | 80.77Cr | 86.16Cr | 120Cr | 120Cr | 450Cr | 483Cr | 708Cr | 1424Cr | 1366Cr | 895Cr | 1727Cr | 2520Cr | 1562Cr | 1422Cr | 1285Cr |
| Enterprise value to EBITDA ratio | 4.25 | 5.81 | 4.78 | 3.78 | 5.40 | 4.47 | 4.60 | 5.45 | 4.77 | 17.87 | 14.30 | 17.08 | 29.89 | 19.96 | 16.03 | 24.63 | 41.85 | 30.19 | 26.50 | 20.63 |
| Debt to equity ratio | 0.12 | 0.80 | 0.60 | 0.51 | 0.49 | 0.44 | 0.27 | 0.48 | 0.64 | 0.71 | 0.58 | 0.54 | 0.49 | 0.51 | 0.63 | 0.48 | 0.88 | 0.98 | 0.84 | 0.68 |
| Return on equity % | 0 | 24.77 | 22.93 | 13.51 | 15.57 | 17.02 | 14.12 | 14.57 | 13.29 | 15.84 | 20.85 | 21.06 | 19.69 | 26.14 | 15.41 | 16.04 | 16.11 | 9.87 | 6.61 | 9.07 |
Hester Biosciences Ltd Ratios
The Hester Biosciences Ltd Ratios page provides a complete fundamental analysis of Hester Biosciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Hester Biosciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Hester Biosciences Ltd (NSE: HESTERBIO, BSE: 524669) is currently trading at ₹2196.40, with a market capitalization of ₹1826.59Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Hester Biosciences Ltd remains a key stock for fundamental analysis using Hester Biosciences Ltd Ratios.
Hester Biosciences Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Hester Biosciences Ltd P/E ratio currently stands at 38.81, making it one of the most tracked metrics in Hester Biosciences Ltd Ratios.
Historically, the Hester Biosciences Ltd P/E ratio has shown strong fluctuations:
- 2025: 38.81
- 2024: 62.57
- 2023: 48.58
- 2022: 58.75
- 2021: 47.36
The decline in Hester Biosciences Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Hester Biosciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.39.
Historical P/B trend:
- 2025: 3.39
- 2024: 4.05
- 2023: 4.62
- 2022: 8.88
Hester Biosciences Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Hester Biosciences Ltd P/S ratio currently stands at 3.43, an important part of Hester Biosciences Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 3.43
- 2024: 3.90
- 2023: 4.86
- 2022: 9.83
A stable or declining Hester Biosciences Ltd P/S ratio indicates cautious market sentiment.
Hester Biosciences Ltd Price to Cash Flow Ratio (P/CF)
The Hester Biosciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.43.
Historical Hester Biosciences Ltd Price to Cash Flow Ratio:
- 2025: 20.43
- 2024: 33.64
- 2023: 112.34
- 2022: 353.52
- 2021: 29.49
The declining Hester Biosciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Hester Biosciences Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Hester Biosciences Ltd EV currently stands at ₹1285Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 1285Cr
- 2024: 1422Cr
- 2023: 1562Cr
- 2022: 2520Cr
Hester Biosciences Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Hester Biosciences Ltd EV/EBITDA ratio is currently 20.63, a key metric in Hester Biosciences Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 20.63
- 2024: 26.50
- 2023: 30.19
- 2022: 41.85
Stable Hester Biosciences Ltd EV/EBITDA indicates balanced valuation.
Hester Biosciences Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Hester Biosciences Ltd D/E ratio is currently 0.68, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.68
- 2024: 0.84
- 2023: 0.98
- 2022: 0.88
Hester Biosciences Ltd maintains moderate leverage with manageable risk.
Return on Equity (ROE %)
The Hester Biosciences Ltd ROE currently stands at 9.07%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 9.07
- 2024: 6.61
- 2023: 9.87
- 2022: 16.11
Declining ROE indicates pressure on profitability.
Hester Biosciences Ltd Ratios Analysis Summary
The Hester Biosciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Hester Biosciences Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Hester Biosciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
